Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259581 · ClinicalTrials.gov registry record · Phase 1
Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin
A Phase 1 study, sponsored by University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03259581 is a Phase 1 study that has completed, run by University of Minnesota. The registered enrollment target is 5 participants.
The verdict
NCT03259581, a Phase 1 study, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
Interventions
- COMBINATION_PRODUCT Transarterial chemoembolization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-02 |
| Est. Completion | 2022-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259581
The ClinicalTrials.gov registry entry for NCT03259581 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Transarterial chemoembolization is the first listed.
NCT03259581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259581 about?
NCT03259581 is a clinical study titled "Safety of Transarterial Chemoembolization (TACE) in the Setting of an Elevated Bilirubin". The aim of this study is to evaluate the safety of selective transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC) in the setting of an elevated total bilirubin, but relatively normal direct bilirubin.
What is the current status of trial NCT03259581?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-01-02. Estimated completion is 2022-02-01.
What interventions are being tested in trial NCT03259581?
The interventions under investigation include: Transarterial chemoembolization (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03259581?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.